|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's range||14.51 - 15.01|
|52-week range||12.03 - 33.09|
|Beta (5Y monthly)||0.94|
|PE ratio (TTM)||N/A|
|Earnings date||27 Feb 2023 - 03 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||42.30|
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at 1:50 p.m. ET. The webcast of the presentation will be contemporaneous
Merus ( NASDAQ:MRUS ) Third Quarter 2022 Results Key Financial Results Revenue: US$6.58m (down 52% from 3Q 2021). Net...
Merus N.V. (MRUS) delivered earnings and revenue surprises of 11.67% and 38.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?